Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
try reading. bulge in alz is due to baby boomer retirement commencing and hitting alz age
financial/political issue is due to the cost of paying for these people, especially when there are much smaller generations following in the work force
keep trying, you [might] get there😆
Yeah, its called the baby boomers retiring. Huge group for the working people to support. But since the next generations are so small (much smaller than America's), it's a huge problem to finance. Hence any drug that cuts alz costs would be a Godsend to Europe. Keep at it, you'll get there.
Hey Abbott: "Who's on first?"
Bishop: Okay. Can you, will we get insomnia data?
Christopher Missling: [indiscernible] insomnia.
Tom Bishop: What about Australia?
Christopher Missling: What about Australia?
Tom Bishop: Okay, the Parkinson's data has been in the wings for a long time. What's the delay?
Christopher Missling: What Parkinson data, please?
Tom Bishop: The Parkinson's next trial.
Christopher Missling: The initiation of the trial? Yes.
LOL so funny: At least I try to provide some value added to this board instead of using it as a room to yell in.
All you do is nitpick other posters. I provide plenty of value add, who do you think went to and posted the annual meeting notes.
And telling managment to execute better is huge value add.
WRONG: A glass of wine is not less expensive than blarcamesine. Blarcamesine can be produced and eventually sole for less than $1.00.
IF that is the selling price, then AVXL stock is near worthless. you have to get a return on your investment, not just a few pennies over manufacturing cost.
Most credible estimates of the charge for alz are in the rage of $12K per year or more. Rett a hard to believe $200K has be bandied about.
better retake that finance class.
Since the trials are run by outsiders, I dont see where it makes much difference.
Either you believe commercialization will happen, or you better sell. So why not get a few more trials rolling before the patents expire.
Perhaps instead of providing useless investment advice, you should stick to paper shufflling like a good bureaucrat.
8 years is far beyond even venture capital timetables to prove viability.
Thanks George. So Bas, George agrees with me.
MIssling throws red meat to AF
AVXL has a new paradigm for sleep management
A glass of port wine is both tastier and cheaper.
Christopher Missling: Yes, after the last 12-week readout, there was an additional safety follow-up
Safety follow up? Thought 273 had long been confirmed safe, what is the issue? And why would a safety followup delay number crunching?
Sounds like BS
Sounds like Icahn was right.
Billionaires like Dell stealing from little guys.
I just wish Dell would make a machine that would last more than 2 years.
How many points did they score?
Enough for a W. and the refs bad call clearly cost them an additional 7 pts. why they didnt challenge it, I dont know.
Now if only Anavex could get into the end zone even once.
LOL "The entire stock market is down today. AVXL is just following the rest of the stock market."
the S&P 5oo is down 0.15%
AVXL is down 11%.
your statement of causation is ludicrous.
gee, even with no warning, the CC tanked the stock
Well done, Herr Missling Inaction.
The Steelers sacked Matt Canada as offensive coach, and the next week the offense generated over 400 yards.
The lack of Anavex "offense" may require a change as well.
No Rett data.
No new trial started.
AD approval by the SLOWEST route?
LOL, the greater length of time for an EMA decision was a reason why this application is going first.
what BS. you should be going the fastest rout to market to get revenues, stop dilution, and prove this company is not a scam.
LIncoln Park and the fact that no trials other than open label are running now.
So Missling is sticking to 2023 milestones?
Rett syndrome: On track for top-line data of potentially pivotal ANAVEX®2-73-RS-003 Phase 2/3 EXCELLENCE pediatric clinical trial.
Parkinson’s disease: Initiation of ANAVEX®2-73 imaging-focused trial and Phase 2b/3 6 months trial.
Schizophrenia: Initiation of ANAVEX®3-71 Phase 2 clinical trial.
Fragile X: Initiation of potentially pivotal ANAVEX®2-73 Phase 2/3 clinical trial.
New Rare disease: Initiation of potentially pivotal ANAVEX®2-73 Phase 2/3 clinical trial.
Better get his tail in gear.
Any thoughts on how long it takes to put an EMA application together?
Any thoughts on how long it takes the EMA to approve?
Going to EMA on alz.
Interesting...considering the story was FDA first, and Rett before alz.
Has the story changed, or is there more going on behind the curtain than we are aware of with the FDA?
Stealth FDA submission already?
Hmm.
I remember when $1249 a share was a common dream
Now we lust for $30.
It would be really hard to hold if we got alz approval and it ran to $100-200.
Not that it would not be worth far more, but lack of shareholder appreciation by mgt is palpable.
Howl long after a quarter ends can a company go without filing it's 10-Q?
I thought it was 45 days...getting close
Not correct: if Anavex were to start new trials for Fragile X, Angelman Syndrome, or any other disease before Rett approval, they would have to spend millions of dollars and add years of research conducting P1, P2 and P3 trials for each disease.
No, P1s are not needed. Safety is established.
A properly designed trial can be used as a P2 or P3. If the FDA approves A2-73 for Rett, Anavex can repurpose the drug and simply run one P3 trial for each disease. IN other words, depending on the circumstances Anavex can call it a P2 or if approved for Rett, rename it a P3. It is still the same trial.
So, yes, there is a freeze...but there's NO good reason for it.
Which is worrysome.
State Street, B of A and Goldman Sachs all dumped shares big in 3rd quarter. Vote of no confidence from Wall Street.
Peer review wont help the stock, PW.
only NDA filings will convince the market that AVXL might have something.
Remember we are going for FDA market approval, not tenure.
You're like talking to a deaf person George.
Buffet only buys stocks in companies with sales and profits. AVXL has neither.
Buffet's idea of a great stock is a railroad, or an insurer. A company with positive cash flow.
Do some research please.